Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMI:TSE International Medical Innovations Inc. -- Ignore unavailable to you. Want to Upgrade?

To: thebeach who wrote (1)	12/12/2000 11:49:04 PM
From: gg cox	Read Replies (1) \| Respond to of 66

IMI INTERNATIONAL MEDICAL INNOVATIONS INC - Notice of Conference Call [470] Canadian Market News from Market News Publishing, Monday, December 11, 2000 at 12:21 IMI International Medical Innovations Inc. will release its fiscal 2001 third-quarter financial results on Friday morning, December 15. With the release of these results, IMI is initiating the practice of holding quarterly conference calls for its investors and others interested in following the company's progress. The conference call will be chaired by IMI's President and CEO, Dr. Brent Norton, and will include Ron Hosking, Vice-President and Chief Financial Officer, and Andrew Weir, Director, Communications. Time: 11:00 a.m. Eastern Time Date: Friday, December 15, 2000 Conference Call No.: 888-666-4830 Please call five minutes prior to the 11:00 a.m. start. If you are unable to participate at that time, you may call 800-558-5253 (U.S. & Canada), then enter Reservation Number 17155225 from 1:00 p.m. on December 15 through December 22 to hear a recording of the entire call. IMI is a Canadian and world leader in predictive medicine, dedicated to developing innovative products for the rapid and early detection of life-threatening conditions, particularly cardiovascular disease and cancer. The Company's lead products are Cholesterol 1,2,3(TM), a three-minute test that measures cholesterol on the skin (on the palm of the hand), and ColorectAlert(TM), a test for early-stage colorectal cancer. IMI is located in Toronto, with shares currently traded on the Toronto Stock Exchange (TSE:IMI - 18,505,199 shares outstanding). TEL: (416) 222-3449 x 27 Mr. Andrew Weir, Director, Communications Email: aweir@imin.ca Web site: www.imin.ca (c) Market News Publishing Inc. Tel:(604) 689-1101 All rights reserved. Fax:(604) 689-1106 MarketbyFax(tm) - To get the NEWS as it happens, call (604) 689-3041. Companies or Securities discussed in this article: Symbol Name BB:IMINF TSE:IMI IMI International Medical Innovations Inc. J

To: thebeach who wrote (1)	1/26/2001 9:45:08 AM
From: gg cox	Read Replies (1) \| Respond to of 66

biz.yahoo.com Wednesday January 24, 2:50 pm Eastern Time Press Release SOURCE: IMI International Medical Innovations Inc. IMI expands skin cholesterol research with Vancouver study Regulatory approvals, partnering negotiations expected to meet targets TORONTO, Jan. 24 /CNW/ - IMI International Medical Innovations Inc. (TSE: IMI - news) announced today that it has undertaken a new clinical trial involving its non-invasive cholesterol test, Cholesterol 1,2,3(TM). The study is being led by Dr. G. B. John Mancini, Head of the Department of Medicine at the University of British Columbia, and will compare Cholesterol 1,2,3(TM) with recognized diagnostic approaches including measures of carotid atheroma burden and of vascular endothelial dysfunction. "This trial may provide another interesting angle for the skin cholesterol method, beyond the core application that is already established," said Dr. Mancini. "We may find, for example, that using Cholesterol 1,2,3 in combination with one of these other methods is more accurate than existing approaches for identifying individuals in need of treatment for cardiovascular disease." "While we continue to expand the scientific foundation for Cholesterol 1,2,3, we are moving forward aggressively on the regulatory and partnering fronts. We are on target with our Canadian and U.S. regulatory submissions. Canadian approval could come as soon as later this quarter. At the same time, our discussions are progressing well with potential partners to market and distribute Cholesterol 1,2,3," said Dr. Norton. Cholesterol 1,2,3 is a rapid, non-invasive test that measures cholesterol in the skin. The test takes three minutes and reads a colour change in a drop of liquid on the palm of the hand. The latest clinical trial results - presented at the American Heart Association meeting in November - showed that skin cholesterol, as measured by Cholesterol 1,2,3, correlated strongly with angiographically proven coronary artery disease. By comparison, blood cholesterol was not as good a correlate as skin cholesterol. These results indicate that this test can effectively predict cardiovascular disease without the needle prick, fasting and waiting associated with blood tests. IMI is a world leader in the field of predictive medicine. The Company is dedicated to developing rapid and non-invasive products for the early detection of life-threatening diseases such as cardiovascular disease and cancer. IMI's head office is in Toronto, and its research facility is at McMaster University in Hamilton, Ontario. Common shares trade on the Toronto Stock Exchange (TSE:IMI, 18,655,199 outstanding). This release contains forward-looking statements that reflect the company's current expectation regarding future events. The forward-looking statements involve risk and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company's quarterly filings. For further information Andrew Weir, Director, Communications, IMI, (416) 222-3449, aweir@imin.ca, www.imin.ca